PhD Matthew Betts
Meine Forschung befasst sich mit den pathologischen- und Verhaltens-veränderungen bei Alterserkrankungen wie zum Beispiel der Parkinson’schen Erkrankung. Eines meiner aktuellen Projekte untersucht wie Degeneration der Regionen des dopaminergen Mittelhirns (SN/VTA) im Alter und bei der Parkinson’schen Erkrankung kognitive Funktionen beeinflussen kann - besonders bei Lernexperimenten und Gedächtniskonsolidierung. Dazu wird eine Kombination aus verschiedenen Hochfeld-MRT-techniken wie zum Beispiel suszeptibilitätsgewichtete Bildgebung (SWI) und Diffusions-Tensor-Imaging (DTI) zusammen mit funktioneller Magnetresonanztomographie genutzt.
Repräsentative Aufnahmen mit 7T-MRT: anatomische T1, T2*-gewichtete Größe, transversale Relaxationsrate (R2*) und quantitative Suszeptibilitätskartierung (QSM).
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
c/o Institut für Kognitive Neurologie und Demenzforschung
Otto-von-Guericke Universität Magdeburg
Leipziger Str. 44
39120 Magdeburg, Deutschland
Telefon: + 49 391 67 250 58
Email:
Beruflicher und wissenschaftlicher Werdegang:
seit 05/2012 | Wissenschaftlicher Mitarbeiter am Deutschen Zentrum für Neurodegenerative |
Erkrankungen e.V., c/o IKND, Otto-von-Guericke-Universität Magdeburg |
10/2007 - 10/2011 | PhD Student am Wolfson Centre for Age-related Diseases (CARD), King's College |
London | |
"Assessing the therapeutic potential of targeting group III metabotrpic glutamate | |
receptor subtypes in the retreatment of Parkinson's disease", Supervised by | |
Dr. Susan Duty |
09/2003 - 06/2007 | MSc in Pharmakologie (mit einjährigem Einsatz in der Industrie), University of Bristol |
Thema: "Development of novel allosteric modulators for iGlu5 and iGlu6 kainate | |
receptors using in silico screening" |
07/2005 - 08/2006 | Praktikum am Eli Lilly Research Centre, Windlesham Surrey, UK |
"Using the technique of in vivo microdialysis to assess the extent of lesion and | |
functional recovery in animal models of Parkinson's disease" | |
Supervised by Dr. Stephen Mitchell |
- In vivo locus coeruleus imaging analysis of the DELCODE study
- Multimodal in vivo imaging in Parkinson’s disease
- Relationship between iron deposition and cognitive decline in ageing
- Role of neuromelanin-sensitive MRI to assess dopaminergic function
- Optimisation and standardisation of in vivo locus coeruleus imaging approaches
Original research publications
Betts MJ, Acosta-Cabronero J, Cardenas-Blanco A, Nestor PJ, Düzel E (under review). High-resolution in vivo characterization of the aging human brain using simultaneous quantitative susceptibility mapping (QSM) and R2* measurements at 7 Tesla.
Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, Nestor PJ (2015). In vivo MRI mapping of brain iron deposition across the adult lifespan. J.Neurosci. (in press)
Betts MJ, O’Neill M, Duty S (2012). Allosteric modulation of the group III mGlu receptor 4 provides functional neuroprotection in the rodent 6-OHDA model of Parkinson’s disease. Br J Pharmacol. Aug;166(8):2317-30
Broadstock M, Austin P, Betts MJ, Duty S (2012). Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol. Feb;165(4b):1034-45
Austin P, *Betts MJ, Broadstock M, O’Neill M, Mitchell S, Duty S (2010). Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson’s disease. Br J Pharmacol. Aug;160(7):1741-5
* Denotes co-first author
Book chapters
Düzel E, Guitart-Masip M, Maaß A, Haemmerer D, Betts M, Speck O, Weiskopf N, Kanowski M (2015). Midbrain fMRI: Applications, limitations and challenges
Conference proceedings
23rd International Society for Magnetic Resonance in Medicine Annual Meeting, Toronto, Canada
Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, Speck O, Nestor PJ (2015).
QSM standardisation routine for unbiased whole-brain analysis
13th International Conference on Alzheimer’s and Parkinson’s Disease, Nice, France
Betts MJ, Liepelt-Scarfone I, Maaß A, Glanz W, Galatzky I, Berg D, Düzel E (2015). Impaired long-term memory for neutral but not emotionally negative stimuli in subjects at risk of Parkinson’s disease
Heider M, Betts MJ, Pertzov Y, Husain M, Düzel E (2015). Working memory binding in ageing: a VBM analysis of structural changes in low and high performing elderly individuals
XIII Magdeburg International Neurobiological Symposium, Magdeburg, Germany
Krauel K, Haynes JD, Heinze HJ, Tegelbeckers J, Pietro L, Perosa V, Breitling C, Guitart-Masip M, Düzel E, Bonath B, Flechtner HH, Betts MJ (2015). Pavlovian congruency in healthy development and attention deficit hyperactivity disorder (ADHD)
Dallas Aging and Cognition Conference, Dallas, USA
Betts MJ, Maaß A, Acosta-Cabronero J, Düzel E (2015). Striatum predicts memory bias for emotionally negative stimuli in young but not elderly adults
Annual Meeting of the Organization for Human Brain Mapping, Hamburg, Germany
Betts MJ, Kaufmann J, Heidel J, Lützkendorf R, Cardenas-Blanco A, Düzel E (2014). Connectivity-based parcellation of the SN/VTA using diffusion tensor imaging at 7 tesla
Maaß A, Betts M, Berron D, Düzel E (2014). 7T fMRI of SN/VTA, locus coeruleus & hippocampus during emotional & reward-related memory encoding
43rd Annual Meeting of the Society for Neuroscience, San Diego, CA, USA
Betts MJ, Kaufmann J, Heidel J, Düzel E (2013). The effects of MR field strength on connectivity-based segmentation of the SN/VTA using diffusion tensor imaging at 3 and 7-tesla
40th Annual Meeting of the Society for Neuroscience, San Diego, CA, USA
Betts M, O’Neill M, Mitchell S, Duty S (2010). Selective activation of the mGlu4 but not mGlu7 group III metabotropic glutamate receptor provides functional neuroprotection in the rat 6-OHDA model of Parkinson’s disease.
XVIII WFN Congress on Parkinson’s Disease and Related Disorders, Miami, USA
Betts M, O’Neill M, Mitchell S, Duty S (2009). Allosteric modulation of group III metabotropic glutamate receptor 4: a potential neuroprotective approach for the treatment of Parkinson's disease. Parkinsonism and Related Disorders 15(Suppl 2):S121
British Pharmacological Society, Winter Meeting, London, UK
Betts M, O’Neill M, Mitchell S, Duty S (2009). Supra-nigral administration of an mGlu4 receptor allosteric potentiator protects against histological and functional deficits in the 6-OHDA lesion rat model of Parkinson’s disease.
6th International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily
Betts M, O’Neill M, Mitchell S, Duty S (2008). The group III mGlu receptor agonist L-AP4 affords both neurochemical and functional neuroprotection against a 6-hydroxydopamine lesion of the substantia nigra in rats. Neuropharmacology 55: 585-638(9)
- Elisa Lancini - Doktorandin, Co-Supervision mit Dr. Dorothea Hämmerer und Prof. Dr. Emrah Düzel
- Johanna Pape - Medizinische Doktorandin
- Laura Neumann - Medizinische Doktorandin
- Sewda Yavari - Medizinische Doktorandin
- Mousumi Saktar - Studentische Hilfskraft